Open AccessCASE REPORT ON DOCETAXEL-INDUCED INTERSTITIAL LUNG DISEASE
Author(s) -
Remya Antony,
S. Swathi Krishna,
Jini James,
Akhilesh Kunoor,
Meenu Vijayan
Publication year - 2017
Publication title -
asian journal of pharmaceutical and clinical research
Language(s) - English
Resource type - Journals
eISSN - 2455-3891
pISSN - 0974-2441
DOI - 10.22159/ajpcr.2017.v10i10.19043
Subject(s) - docetaxel , medicine , lung cancer , taxane , interstitial lung disease , adverse effect , incidence (geometry) , oncology , chemotherapy , disease , population , adverse drug reaction , lung , cancer , drug , breast cancer , pharmacology , physics , environmental health , optics
Docetaxel belongs to taxane family of antineoplastic agents that are indicated for the treatment of locally advanced or metastatic non-small-cell lung cancer. Docetaxel is associated with many adverse effects, and pulmonary reaction has an incidence of 41%. However, interstitial pulmonary disease is found to occur only in <1% of the population as per the post-marketing surveillance reports. Here, we report a case of docetaxel-induced interstitial lung disease (ILD). The patient information and details were collected using the hospital information system. The adverse drug reaction (ADR) of ILD occurred after 5 cycles of chemotherapy with docetaxel at a dose of 60 mg/m2 that is 80 mg IV. The causality of the event in our case was assessed using the Naranjo ADR probability scale which marked a score of 7 (probable). It is necessary that all physicians be aware of the reaction and to closely monitor clinicoradiological and functional status of the patients at regular intervals after administration of docetaxel.